Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong revenue growth and improved net loss, but also highlights increased R&D expenses and a recent equity offering, which can dilute share value. The lack of strategic updates or risk discussions, coupled with unclear management responses in the Q&A, suggests uncertainty. Given the market cap, these mixed signals balance out to a neutral sentiment, indicating a likely stock price fluctuation within -2% to 2% over the next two weeks.
Key Financial Performance
Revenue Revenue for Q1 2026 was $12.5 million, representing a 25% increase year-over-year, driven by strong sales of our lead product.
Research and Development Expenses R&D expenses were $18 million, up 10% year-over-year, primarily due to increased investment in clinical trials for our pipeline products.
Net Loss Net loss for the quarter was $8 million, an improvement from $10 million in Q1 2025, attributed to higher revenue and cost management efforts.
Cash and Cash Equivalents Cash and cash equivalents stood at $150 million as of March 31, 2026, compared to $140 million a year ago, reflecting proceeds from a recent equity offering.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alan Krasner
Alexander
Brian Skorney
Chief Endocrinologist
Co
Director
Division Brian
Division Fye
Division Gavin
Division Jin
Division Maxwell
Division Nicholas
Division PM
Diwakar Head
Diwakar Senior
EDT Hello
Endocrinologist Tobin
Fye JPMorgan
Gavin Clark
Hello Crinetics
Incorporated Research
Institutional
Instructions conference
Jin Law
LLC Research
Lorusso TD
Nicholas Lorusso
Officer Alan
Officer Schwartz
PM EDT
Relations Slide
Research Division
Results Instructions
Skorney Baird
conference Diwakar
CRNX Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call shows strong revenue growth and improved net loss, but also highlights increased R&D expenses and a recent equity offering, which can dilute share value. The lack of strategic updates or risk discussions, coupled with unclear management responses in the Q&A, suggests uncertainty. Given the market cap, these mixed signals balance out to a neutral sentiment, indicating a likely stock price fluctuation within -2% to 2% over the next two weeks.
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call highlights a strong revenue growth forecast (15%-20%) and improved operating margins, alongside successful product launches and market expansion in endocrinology. Despite a net loss, cost-cutting measures have improved financial health. The absence of explicit risks further supports a positive outlook. With a market cap of $3.4 billion, the positive guidance and strategic initiatives are likely to result in a moderate stock price increase of 2% to 8%.
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call highlights strong product development and market strategy, especially with the PALSONIFY launch and its appeal to both patients and prescribers. The Q&A section indicates effective execution and positive reception, despite minor uncertainties in payer approval timing. Financial guidance shows controlled cash usage, and the company is well-capitalized. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
CRNX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
